Jump to content

Phyllodes tumor

From Wikipedia, the free encyclopedia
Phyllodes tumor
Micrographof a phyllodes tumor (right of image) with the characteristic long clefts and myxoid cellular stroma. Normal breast andfibrocystic changeare also seen (left of image).H&E stain.
Phullonmeans 'leaf' in Greek. It is appropriately named to describe the characteristic papillary projections seen on histology in phyllodes tumors.

Phyllodes tumors(fromGreek:phullon), are a rare type ofbiphasicfibroepithelial massthat form from the periductal stromal and epithelial cells of thebreast.[1]They account for less than 1% of all breastneoplasms.[2]They were previously termedcystosarcoma phyllodes,coined byJohannes Müllerin 1838, before being renamed tophyllodes tumorby the World Health Organization in 2003.[3]Phullon,which means 'leaf' in Greek, describes the unique papillary projections characteristic of phyllodes tumors on histology.[1]Diagnosis is made via a core-needle biopsy and treatment is typically surgical resection with wide margins (>1 cm), due to their propensity to recur.[4]

Signs and symptoms

[edit]
Phyllodes tumor in mammography
Anatomopathological results of phyllodes tumor.

Phyllodes tumors typically present as a firm, mobile, and palpable mass that is painless in nature.[5]On physical examination, the mass can demonstrate a smooth or nodular texture depending on its size.[3]In addition, larger masses can stretch the overlying breast tissue leading to nipple retraction, chest wall fixation, and in advanced cases, ulceration from pressurenecrosis.[6]

Phyllodes tumors can grow to a variety of sizes, ranging from 0.8 to 40 cm, with the average tumor growing to between 4 and 8 cm.[7]Their growth can be slow, rapid, or demonstrate alternating growth patterns.[5]A notable feature, however, is that their growth rarely regresses, a distinguishing feature fromfibroadenomaswhich tend to change in size based on a female's menstrual cycle.[8]

Causes

[edit]

Experts are unsure of the exact etiology of phyllodes tumors.[5]Genetically, phyllodes tumors have shown to have a higher incidence with conditions such asLi-Fraumeni syndromeandBRCA1/BRCA2mutations.[5]In addition, males with a history ofgynecomastiahave shown an increased incidence of developing a phyllodes tumor.[5]

Mechanism

[edit]

The pathogenesis behind the development of a phyllodes tumor is not well-defined.[9]Some theories suggest a genetic cause while other literature supports the involvement of hormone and growth factor receptors, cell signal transduction pathways, and cell cycle markers.[8][9][10]Certain receptors includeestrogen/progesterone,glucocorticoid,andHER2.[9]The most well-studied cell signal transduction pathway includes theWnt pathway,which is a highly conserved genetic pathway between species.[9]In theWnt pathway,gene transcription viaB-cateninis a highly regulated process by proteins including, but not limited to,c-myc,c-jun,Fra,and cyclin D1.[9]Mutation of any these proteins can lead to the un-regulated, rapid growth characteristic of phyllodes tumors.[9]

In addition, vascular factors promotingangiogenesishave been shown to further promote growth of these breast masses.[9]These proteins include vascular endothelial growth factor (VEGF), Hypoxia-inducible factor-1a, Platelet-derived growth factor, endothelin-1, and nitrogen oxide synthase.[9]The increased expression of these angiogenic factors reflects the increasedangiogenesisseen in higher grade phyllodes tumors.[9]

Genes that have been associated with a higher incidence of phyllodes tumors include Mediator Complex Subunit 12 (MED12) exon 2, Telomerase Reverse Transcriptase (TERT) promoter, and Retinoic Acid Receptor Alpha (RARA); important genes for regulatingDNA synthesis.[10]

The current theory behind the development of phyllodes tumors involves the interaction between each of these pathways to some degree and how they alter the normal interaction of the breast epithelial-stromal tissue.[9]

Diagnosis

[edit]

Diagnostic techniques

[edit]

Radiographical imagingis the first-line test for identifying a phyllodes tumor.[11]Despite their propensity to grow rapidly and deform the overlying breast tissue, approximately 20% of phyllodes tumors can present as a nonpalpable mass on screening mammography.[12]Other imaging tools used to assess the size and spread of a phyllodes tumor includeultrasoundandmagnetic resonance imaging(MRI).[11]None of these imaging tools are definitive tests for differentiating a phyllodes tumor from a benignfibroadenoma.[13]Phyllodes tumors can only be diagnosedhistologically,as they tend to have many overlapping features with other breast masses on physical examination and radiological imaging.[11]

Acore needle biopsyis the primary tool used to provide a definitive diagnosis for phyllodes tumors.[11]Other biopsy techniques includefine-needle aspirationand excisional biopsy. Followingbiopsy,histological and gross examination is performed which helps clinicians better grade and classify the phyllodes tumor.[11]

Classification

[edit]

Phyllodes tumors are part of a group of breast diseases called cellularfibroepithelial lesions.[8]This term incorporates a spectrum of diseases ranging from a benignfibroadenomato a malignant phyllodes tumor, with numerous variants in between.[14]They are classified byICD-O,not byMeSH.[14]

Phyllodes tumors may be consideredbenign,borderline,ormalignantdepending upon their histological features, including stromal cellularity, infiltration of the epithelial-stromal interface, and mitotic activity.[15]Due to their propensity to metastasize and grow quickly, almost all phyllodes tumors are regarded as having malignant potential and treated accordingly.[15]A large case series from the MD Anderson Cancer Center reported the incidence of each type of phyllodes tumor as benign (58%), borderline (12%), and malignant (30%).[16]

Gross image of an excised phyllodes tumor.

Malignant phyllodes tumors can behave similarly tosarcomasleading to development ofblood-bornemetastases.[16]Approximately 10% of phyllodes tumor develop distant metastases and this occurrence is higher (20%) in patients with histological-identified malignant tumors.[16]The most common site for distant metastases include the lung, bone, and abdominal viscera.[17]In more insidious cases, theparotidregion has also been described in literature.[18]

Histopathologic classification[19]
Benign Borderline Malignant
Margin Pushing Infiltrating
Stromal atypia Minimal Moderate Severe
Mitoses per 10HPF <5 5 to 9 ≥10
Stromal overgrowth Absent Present

Prevention and screening

[edit]

There is no evidence-based recommendations for screening or preventative measures for early detection of phyllodes tumors.[20][21]

In patients with a prior history of a phyllodes tumor, the follow-up recommendations are employed on a case-by-case basis depending upon the grade and stage of the treated tumor.[20]

Patients who have not had amastectomyshould continue regularbreast cancer screeningbased on the recommendations by theUnited States Preventative Services Task Force.[22]

Treatment

[edit]

The most common, curative treatment for a phyllodes tumor is wide surgical excision with greater than 1 cm margins.[15]Other than surgery, there is no definite cure for a phyllodes tumor as chemotherapy and radiation therapy have not proven effectiveness.[15]The risk of developing local recurrence or metastases is related the histologic grade and mitotic activity of the tumor.[15]Despite proper surgical excision, a high percentage of surgeries performed to treat a phyllodes tumor demonstrate incomplete excision margins that require additional revision surgery.[23]Radiation treatment, after breast-conserving surgery with negative margins, may significantly reduce the local recurrence rate for borderline and malignant tumors.[24]A study performed in 2012 derived a risk calculator for relapse risk of phyllodes tumors after surgery.[25]

Prognosis

[edit]

Theprognosisof phyllodes tumor is good with an overall 87% 10-year survival rate.[5]After wide-margin surgical excision, 98.7% of benign phyllodes tumors and 80% of borderline were cured.[25]In rare cases where the tumor has metastasized, the prognosis is poor.[5]This most commonly occurs in cases of malignant grade phyllodes tumor.[5]

Epidemiology

[edit]

Phyllodes tumors account for approximately 1% of all breast neoplasms.[2]They primarily occur in adult women, with very few examples reported in adolescents. Incidence is most common between the ages of 40 and 50, prior to the onset ofmenopause.[26]For comparison, this is about 15 years older than the typical age of patients with afibroadenoma,a common differential diagnosis in patients with a suspected phyllodes tumors.[26]Younger women have a higher chance of having a benign phyllodes tumor, while older women are more likely to have higher-grade tumors.[23]

References

[edit]
  1. ^abHasdemir S, Tolunay Ş, Özşen M, Gökgöz MŞ (January 2020)."Phyllodes Tumor of the Breast: A Clinicopathological Evaluation of 55 Cases".European Journal of Breast Health.16(1): 32–38.doi:10.5152/ejbh.2019.4709.PMC6939715.PMID31912011.
  2. ^abKonstantakos AK, Graham DJ (September 2003)."Cystosarcoma phyllodes tumors in men".The American Surgeon.69(9): 808–811.doi:10.1177/000313480306900916.PMID14509333.S2CID26206134.
  3. ^abZhou ZR, Wang CC, Yang ZZ, Yu XL, Guo XM (November 2016)."Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence".Journal of Thoracic Disease.8(11): 3361–3368.doi:10.21037/jtd.2016.11.03.PMC5179374.PMID28066617.
  4. ^Komenaka IK, El-Tamer M, Pile-Spellman E, Hibshoosh H (September 2003)."Core needle biopsy as a diagnostic tool to differentiate phyllodes tumor from fibroadenoma".Archives of Surgery.138(9): 987–990.doi:10.1001/archsurg.138.9.987.PMID12963656.
  5. ^abcdefghLimaiem F, Kashyap S (2022).Phyllodes Tumor Of The Breast.Treasure Island (FL): StatPearls Publishing.PMID31082182.Retrieved2023-01-18.{{cite book}}:|work=ignored (help)
  6. ^Khan SA, Badve S (April 2001). "Phyllodes tumors of the breast".Current Treatment Options in Oncology.2(2): 139–147.doi:10.1007/s11864-001-0056-y.PMID12057132.S2CID34616186.
  7. ^Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, et al. (February 2008). "Phyllodes tumor of the breast".International Journal of Radiation Oncology, Biology, Physics.70(2): 492–500.doi:10.1016/j.ijrobp.2007.06.059.PMID17931796.
  8. ^abcHartmann TC, Hanna MW (October 2022)."Delayed Conversion of a Fibroadenoma Into a Large Phyllodes Tumor: A Case Report".Cureus.14(10): e30795.doi:10.7759/cureus.30795.PMC9701494.PMID36447717.
  9. ^abcdefghijKarim, Rooshdiya Z.; Scolyer, Richard A.; Tse, Gary M.; Tan, Puay-Hoon; Putti, Thomas C.; Lee, C. Soon (February 2009)."Pathogenic mechanisms in the initiation and progression of mammary phyllodes tumours".Pathology.41(2): 105–117.doi:10.1080/00313020802579342.ISSN0031-3025.PMID19152185.S2CID34470088.
  10. ^abSim, Yirong; Ng, Gwendolene Xin Pei; Ng, Cedric Chuan Young; Rajasegaran, Vikneswari; Wong, Suet Far; Liu, Wei; Guan, Peiyong; Nagarajan, Sanjanaa; Ng, Wai Yee; Thike, Aye Aye; Lim, Jeffrey Chun Tatt; Nasir, Nur Diyana Binte Md; Tan, Veronique Kiak Mien; Madhukumar, Preetha; Yong, Wei Sean (2019-10-23)."A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions".BMC Medical Genomics.12(1): 142.doi:10.1186/s12920-019-0588-2.ISSN1755-8794.PMC6813086.PMID31647027.
  11. ^abcdeBoutas, Ioannis; Kontogeorgi, Adamandia; Dimas, Dionysios; Koufopoulos, Nektarios; Genitsaridi, Sofia-Maria; Sitara, Kyparissia; Kalantaridou, Sophia; Dimitrakakis, Constantine (October 2022)."Local recurrence for phyllodes tumours of the breast: Systematic review and meta-analysis".Oncology Letters.24(4): 353.doi:10.3892/ol.2022.13473.ISSN1792-1082.PMC9478605.PMID36168312.
  12. ^Macdonald, O. Kenneth; Lee, Christopher M.; Tward, Jonathan D.; Chappel, Craig D.; Gaffney, David K. (2006-11-01)."Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program".Cancer.107(9): 2127–2133.doi:10.1002/cncr.22228.ISSN0008-543X.PMID16998937.S2CID35411155.
  13. ^"UpToDate".www.uptodate.com.Retrieved2023-01-26.
  14. ^abDeen SA, McKee GT, Kissin MW (February 1999). "Differential cytologic features of fibroepithelial lesions of the breast".Diagnostic Cytopathology.20(2): 53–56.doi:10.1002/(SICI)1097-0339(199902)20:2<53::AID-DC1>3.0.CO;2-T.PMID9951596.S2CID21831164.
  15. ^abcde Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. (January 2016)."Phyllodes tumours of the breast: a consensus review".Histopathology.68(1): 5–21.doi:10.1111/his.12876.PMC5027876.PMID26768026.
  16. ^abcMajeski, James; Stroud, Jason (2012)."Malignant phyllodes tumors of the breast: a study in clinical practice".International Surgery.97(2): 95–98.doi:10.9738/CC79.1.ISSN2520-2456.PMC3723204.PMID23102073.
  17. ^Khanal, Suman; Singh, Yogendra P.; Bhandari, Anuja; Sharma, Rashmi (December 2018)."Malignant phyllodes tumor with metastases to lung, adrenal and brain: A rare case report".Annals of Medicine and Surgery (2012).36:113–117.doi:10.1016/j.amsu.2018.10.030.ISSN2049-0801.PMC6230968.PMID30455875.
  18. ^Zhang, John Z.; Gu, Mai (2003)."Malignant phyllodes tumor of the breast metastatic to the parotid gland diagnosed by fine needle aspiration biopsy. A case report".Acta Cytologica.47(2): 253–258.doi:10.1159/000326512.ISSN0001-5547.PMID12685197.S2CID3364081.
  19. ^Makhija D, Shah H, Bothra J, Jayaswal S (December 2016)."An adolescent with a phyllodes tumor: A case report and review".International Journal of Pediatrics & Adolescent Medicine.3(4): 180–183.doi:10.1016/j.ijpam.2016.03.005.PMC6372421.PMID30805490.
  20. ^abPatel, Shreyaskumar R.; Zagars, Gunar K.; Pisters, Peter W. T. (June 2003)."The follow-up of adult soft-tissue sarcomas".Seminars in Oncology.30(3): 413–416.doi:10.1016/s0093-7754(03)00101-5.ISSN0093-7754.PMID12870143.
  21. ^Grabowski, Julia; Salzstein, Sidney L.; Sadler, Georgia R.; Blair, Sarah L. (October 2007)."Malignant phyllodes tumors: a review of 752 cases".The American Surgeon.73(10): 967–969.doi:10.1177/000313480707301007.ISSN0003-1348.PMID17983058.S2CID20319387.
  22. ^"Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce".www.uspreventiveservicestaskforce.org.Retrieved2023-01-23.
  23. ^abGuillot E, Couturaud B, Reyal F, Curnier A, Ravinet J, Laé M, et al. (2011)."Management of phyllodes breast tumors".The Breast Journal.17(2): 129–137.doi:10.1111/j.1524-4741.2010.01045.x.PMID21251125.S2CID7074922.
  24. ^Barth RJ, Wells WA, Mitchell SE, Cole BF (August 2009)."A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors".Annals of Surgical Oncology.16(8): 2288–2294.doi:10.1245/s10434-009-0489-2.PMC5053421.PMID19424757.
  25. ^abReinfuss, M.; Mituś, J.; Duda, K.; Stelmach, A.; Ryś, J.; Smolak, K. (1996-03-01)."The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases".Cancer.77(5): 910–916.doi:10.1002/(sici)1097-0142(19960301)77:5<910::aid-cncr16>3.0.co;2-6.ISSN0008-543X.PMID8608483.S2CID46154369.
  26. ^abBernstein, L.; Deapen, D.; Ross, R. K. (1993-05-15)."The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast".Cancer.71(10): 3020–3024.doi:10.1002/1097-0142(19930515)71:10<3020::aid-cncr2820711022>3.0.co;2-g.ISSN0008-543X.PMID8387873.S2CID21014296.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Phyllodes_tumor&oldid=1215121801"